From: Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders
Symptom | Percent of participants experiencing the symptom [n (%)] | ||
---|---|---|---|
Overall (N = 125) | 1 spray administered (n = 28) | ≥ 2 sprays administered (n = 97) | |
Confusion | 76 (61%) | 17 (61%) | 59 (61%) |
Agitated/Angry | 63 (50%) | 15 (54%) | 48 (49%) |
Body weakness | 63 (50%) | 13 (46%) | 50 (52%) |
Nausea | 61 (49%) | 13 (46%) | 48 (49%) |
Shivering | 58 (46%) | 14 (50%) | 44 (45%) |
Sweating | 52 (42%) | 12 (43%) | 40 (41%) |
Headaches | 50 (40%) | 8 (29%) | 42 (43%) |
Dizziness | 46 (37%) | 8 (29%) | 38 (39%) |
Vomiting | 42 (34%) | 10 (36%) | 32 (33%) |
Body pain | 26 (21%) | 6 (21%) | 20 (21%) |
Nasal congestion | 15 (12%) | 4 (14%) | 11 (11%) |
Nasal dryness | 15 (12%) | 0 (0%) | 15 (15%) |
Yawning | 13 (10%) | 2 (7%) | 11 (11%) |
Other | 11 (9%) | 1 (4%) | 10 (10%) |
None | 2 (2%) | 0 (0%) | 2 (2%) |